Essential Hypertension
Conditions
Brief summary
The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of BR1015-A and co-administration of BR1015-3 and BR1015-2 in healthy volunteers under fed conditions
Interventions
Sponsors
Boryung Pharmaceutical Co., Ltd
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Subjects with a body mass index (BMI) of more than 18.0 kg/m² and less than 30.0 kg/m² at the screening visit. * Subjects who provide written informed consent voluntarily after receiving and understanding sufficient explanation regarding the purpose and procedures of the clinical trial, the characteristics of the investigational product, and the expected adverse events. * Subjects who agree to use a highly effective method of contraception, excluding hormonal contraceptives, from the time of signing the written informed consent form until 14 days after the last administration of the investigational product, and who agree not to donate sperm or ova during this period. This requirement applies to the subject and, as applicable, to their spouse or sexual partner in order to prevent pregnancy.
Exclusion criteria
* Subjects who have taken drugs that induce or inhibit metabolizing enzymes, such as barbiturates, within 30 days prior to the first administration of the investigational product, or who have taken any prescription drugs, over-the-counter drugs (OTC), herbal medicines, or dietary supplements within 10 days prior to the first administration that may interfere with the conduct of the study (however, participation may be allowed considering the pharmacokinetics and pharmacodynamics, including potential interactions with the investigational product and the half-life of concomitant drugs). * Subjects with a medical history of gastrointestinal resection or gastrointestinal diseases that may affect the absorption of drugs (except for simple appendectomy or hernia surgery). * Subjects who have participated in other clinical trials (including bioequivalence studies) and received investigational products within 6 months prior to the first administration of this study. For this criterion, the 6-month period is counted from the last administration date of the investigational product in the previous study. * Subjects who are unable to discontinue consumption of foods that may affect the absorption, distribution, metabolism, or excretion of the investigational product (e.g., raw grapefruit, grapefruit juice, or foods containing grapefruit) from 48 hours prior to the first administration of the investigational product until the collection of the last pharmacokinetic blood sample. * Subjects who, for reasons other than those specified in the inclusion and
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| AUCt of Fimasartan | From pre-dose (0 hour) through 48 hours post-dose in each period (Periods 1-4). | Area under the Plasma Concentration-Time Curve from Time Zero to Time t of Fimasartan |
| AUCt of Indapamide | From pre-dose (0 hour) through 72 hours post-dose in each period (Periods 1-2). | Area under the Plasma Concentration-Time Curve from Time Zero to Time t of Indapamide |
| Cmax of Fimasartan | From pre-dose (0 hour) through 48 hours post-dose in each period (Periods 1-4). | Maximum Concentration of Drug in Plasma of Fimasartan |
| Cmax of Indapamide | From pre-dose (0 hour) through 72 hours post-dose in each period (Periods 1-2). | Maximum Concentration of Drug in Plasma of Indapamide |
Contacts
CONTACTSoo Hee Kim
Outcome results
None listed